


Natural Products

Concise Synthesis of the Tricyclic Core of Platencin**

Sang Young Yun, Jun-Cheng Zheng, and Daesung Lee*


Platensimycin (**1**)^[1] and platencin (**2**)^[2] which are structurally related antibiotics, were recently discovered through a systematic target-based whole-cell high-throughput screen-



ing. These novel bacterial metabolites show potent Gram-positive antibacterial activity against antibiotic-resistant pathogens.^[3] Platencin (**2**), isolated from a new strain of *Streptomyces platensis* MA 7339 found in a soil sample collected in Spain, exhibits MIC values in the range 0.14–9.4 μM against *S. aureus*, MRSA, vancomycin-resistant enterococci, and *Streptococcus pneumoniae*. Further biochemical assays identified **2** as a potent and dual inhibitor of the fatty acid biosynthesis condensing enzymes β -ketoacyl-(acyl-carrier-protein) synthase II (FabF) and III (FabH), with IC_{50} values of 1.95 and 3.91 $\mu\text{g mL}^{-1}$, respectively.^[2] As a result of the promising antibacterial activities and novel structures of **1** and **2**, many insightful synthetic approaches have been developed since the first total synthesis of platensimycin by Nicolaou et al.^[4,5] Recently, Nicolaou et al. also reported the first total synthesis of platencin (**2**).^[6] Herein, we report a concise synthetic route to the tricyclic core of platencin which relies on a radical-mediated construction of the central bicyclo[2.2.2]octane moiety as the key feature.^[7]

Our retrosynthetic plan for platencin (**2**) is depicted in Scheme 1. Synthesis of the natural product is expected to be completed by the final-stage elaboration of the core **3** through a

three-carbon homologation followed by formation of an amide bond with 3-amino-2,4-dihydroxybenzoic acid.^[6] An intramolecular aldol reaction or ring-closing metathesis (RCM) reaction is envisioned for the formation of cyclohexenone moiety of **3** starting from ketoaldehyde **4** or from an appropriate diene RCM precursor **5**. These precursors would be elaborated from **6** by a two-carbon homologation. A skeletal rearrangement of the initially formed radical intermediate **9** to the required bicyclo[2.2.2]octane **7** would be initiated by the addition of a tributylstannyl radical to the pendant alkyne moiety of precursor **10**.^[7] The cyclohexene-



Scheme 1. Retrosynthetic analysis of platencin (**2**).


based 1,6-enyne **10**, in turn, could be prepared by desymmetrization of *meso*-anhydride **12** to form lactone **11** followed by propargylation.

The preparation of radical ring-closure precursor **10** commenced with the conversion of cyclic anhydride **12** into lactone **11** by reduction with DIBAL followed by treatment with acid (Scheme 2). For the asymmetric synthesis, **12** was desymmetrized to form the carboxylic acid half ester **13** by using the procedure of Deng and co-workers.^[8] Compound **13** was converted into acid chloride **14** and subsequently reduced then lactonized to give **11**.^[9] Propargylation of **11** (LDA, propargyl bromide) formed **15**, which was subsequently

[*] Dr. S. Y. Yun, Dr. J.-C. Zheng, Prof. D. Lee
Department of Chemistry
University of Illinois at Chicago
845 West Taylor Street, Chicago, IL 60607 (USA)
Fax: (+1) 312-996-0431
E-mail: dsunglee@uic.edu

[**] We gratefully acknowledge the University of Illinois at Chicago for their support. We thank Dr. Furong Sun (UIUC) for mass spectrometry measurements.


Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.200801587>.



Scheme 2. Construction of the bicyclo[2.2.2]octane moiety: a) DIBAL (2.1 equiv), THF, -78°C to RT over 1 h; 50% aq H_2SO_4 , 0°C , 4 h, 92%; b) LDA (1.1 equiv), THF, -78°C ; $\text{C}_3\text{H}_7\text{Br}$, -78°C to RT over 1 h, 89%; c) LAH (1.5 equiv), THF, 0°C , 1 h, 95%; d) Ac_2O (2.2 equiv), Pyr, DMAP, CH_2Cl_2 , 30 min, 99%; e) Bu_3SnH (1.5 equiv), AIBN, toluene, 100°C , 1 h; SiO_2 , 100°C , 30 min, 51% ($\text{R}=\text{H}$), 67% ($\text{R}=\text{Ac}$); f) $(\text{DHQD})_2\text{AQN}$ (**A**; 8 mol%), MeOH (10 equiv), Et_2O , -20°C , 72 h, 99%; g) $(\text{COCl})_2$ (6 equiv), CH_2Cl_2 , -78°C , 30 min; h) NaBH_4 (2 equiv), MeOH, THF, -78°C , 30 min; i) TsOH (12 mol%), toluene, 100°C , 8 h, 89% (over 3 steps). AIBN = azobisisobutyronitrile; $(\text{DHQD})_2\text{AQN}$ = bis(dihydroquinidine) anthraquinone; DIBAL = diisobutylaluminum hydride; DMAP = 4-(dimethylamino)pyridine; LDA = lithium diisopropylamide; LAH = lithium aluminum hydride; Pyr = pyridine; Ts = *para*-toluenesulfonyl.

reduced and afforded **10a**. An initial attempt at radical-mediated cyclization of **10a** provided bicyclo[2.2.2]octane **6a** in marginal yield (51%). The corresponding diacetate **10b** gave a slightly improved yield of **6b** (67%) under the same reaction conditions (Bu_3SnH , AIBN, toluene, 100°C ; then SiO_2).^[10] The destannylation of **7** was efficiently achieved by adding silica gel after completion of the reaction but before cooling.


The final steps for the synthesis of enone **3** began with mono protection of diol **6a** (Scheme 3). Diacetate **6b** was converted into diol **6a** (K_2CO_3 , MeOH, 96%), which was then treated with sodium hydride (2 equiv, THF) and TBSCl



Scheme 3. The intramolecular aldol approach: a) K_2CO_3 (2.5 equiv), MeOH, 1 h, 96%; b) NaH (2 equiv), TBSCl (1 equiv), THF, -78°C to RT over 30 min, 90%; c) PCC (2 equiv), 4-Å M.S., CH_2Cl_2 , 40 min; d) $\text{Ph}_3\text{PCH}_2\text{OMeCl}$ (2 equiv), $n\text{BuLi}$, THF, -78°C to -20°C over 30 min; then -20°C to RT over 30 min; e) NBS (1 equiv), THF/ H_2O (10:1), 0°C , 1 h; aq NH_4Cl , Zn (3 equiv); f) MeMgBr (1.5 equiv), THF, 0°C , 30 min, 45% (ca. 1:1 mixture of diastereomers; over 4 steps); g) TBAF (1.1 equiv), THF, 0°C , 30 min, 85%; h) $(\text{COCl})_2$ (3 equiv), DMSO (6 equiv), CH_2Cl_2 , Et_3N (6 equiv), -78°C ; i) NaOH (5 equiv), EtOH, 24 h, 60% (over 2 steps). DMSO = dimethyl sulfoxide; M.S. = molecular sieves; NBS = *N*-bromosuccinimide; PCC = pyridinium chlorochromate; TBAF = tetrabutylammonium fluoride; TBS = *tert*-butyldimethylsilyl.

(1 equiv) at low temperature (-78°C) to provide a mixture of **16a** and **16b** (ca. 2:1) in excellent yield (90%).^[11] Oxidation of the primary alcohol of **16a** followed by treatment with triphenylmethoxymethylphosphorane yielded methyl enol ether **17**. Attempted hydrolysis of **17** (2N HCl , THF) proceeded through acid-catalyzed hydration to form **19** via **18**. Gratifyingly, treatment of **17** with NBS in aqueous THF at low temperature gave the α -bromoaldehyde, which was directly treated with zinc powder to give aldehyde **20**. The addition of methyl Grignard reagent to **20** led to a separable mixture of diastereomeric alcohols **21** (ca. 1:1; 45% overall yield from **16a**). Removal of the TBS group was followed by global oxidation to give the corresponding ketoaldehyde **4**, and a subsequent intramolecular aldol/dehydration^[5g, 6a] afforded enone **3** in good yield (60% over 2 steps).

Although **16b** could be recycled to form **16a** through a deprotection/reprotection cycle, an RCM-based approach was developed to facilitate the use of **16b**. As shown in Scheme 4, **16b** was elaborated to **22** by a three-step sequence involving oxidation with PCC, a Wittig reaction, and removal of the TBS group (73% over 3 steps). One-carbon homologation of **22** to give the corresponding unstable aldehyde **23** followed by addition of vinyl Grignard reagent set the stage for RCM of the diene,^[12] which delivered allylic alcohol **24** as an inconsequential mixture (ca. 1:1) upon treatment with the second-generation Grubbs catalyst.^[13] Manganese dioxide mediated oxidation of **24** afforded enone **3** in 86% yield. The



Scheme 4. RCM approach for the construction of enone **3**: a) PCC (2 equiv), 4-Å M.S., CH₂Cl₂, 30 min; b) Ph₃PCH₃Br (3 equiv), *n*BuLi, −78 to 0°C over 30 min; then 0°C, 30 min; c) TsOH (5 mol%), MeOH, 1 h, 73% (over 3 steps); d) PCC (2 equiv), 4-Å M.S., CH₂Cl₂, 30 min; e) Ph₃PCH₂OMeCl (2.5 equiv), *n*BuLi, THF, −78 to −20°C over 30 min; then −20°C to RT over 30 min; NBS (1 equiv), THF/H₂O (10:1), −20 to 0°C over 1 h; then aq NH₄Cl, Zn (3 equiv); f) VinylMgBr (1.5 equiv), THF, 0°C, 1 h, 39% (ca. 1:1 mixture of diastereomers; over 4 steps); g) Grubbs II catalyst (5 mol%), CH₂Cl₂, 40°C, 4 h, 95%; h) MnO₂ (8 equiv), CH₂Cl₂, 1 h, 86%.

¹H and ¹³C NMR spectra of **3** are identical to those reported by Nicolaou et al.^[6a]

In conclusion, we have achieved a concise synthesis (14 steps in the shortest sequence with 10% overall yield) of the bridged tricyclic enone core **3**, a key advanced intermediate in the total synthesis of platencin by Nicolaou et al. Our route highlights the radical-mediated construction of a key building block through a skeletal rearrangement. An intramolecular aldol reaction and an RCM reaction were employed to complete the core cyclohexenone moiety of platencin. A Lewis base catalyzed desymmetrization of a cyclic anhydride was utilized to introduce appropriate chirality. We are currently pursuing the asymmetric total synthesis of both platencin and platensimycin starting from chiral building block **15**.

Received: April 4, 2008

Published online: June 11, 2008

Keywords: antibiotics · natural products · radical cyclization · ring-closing metathesis · total synthesis

- [1] a) J. Wang et al., *Nature* **2006**, *441*, 358; b) S. B. Singh et al., *J. Am. Chem. Soc.* **2006**, *128*, 11916; additions and corrections: S. B. Singh et al., *J. Am. Chem. Soc.* **2006**, *128*, 15547; c) S. B.

- Singh, K. B. Herath, J. Wang, N. Tsou, R. G. Ball, *Tetrahedron Lett.* **2007**, *48*, 5429; d) S. B. Singh, J. Wang, A. Basilio, O. Genilloud, P. Hernandez, J. R. Tormo, WO 2005009391, **2005**.
[2] a) J. Wang et al., *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 7612; b) H. Jayasuriya et al., *Angew. Chem.* **2007**, *119*, 4768; *Angew. Chem. Int. Ed.* **2007**, *46*, 4684.
[3] a) H. Pearson, *Nature* **2002**, *418*, 469; b) C. T. Walsh, *Nat. Rev. Microbiol.* **2003**, *1*, 65; c) S. B. Singh, J. Barrett, *Biochem. Pharmacol.* **2006**, *71*, 1006.
[4] For biosynthesis, see: a) K. B. Herath, A. B. Attygalle, S. B. Singh, *J. Am. Chem. Soc.* **2007**, *129*, 15422; for a review on synthetic studies, see: b) K. Tiefenbacher, J. Mulzer, *Angew. Chem.* **2008**, *120*, 2582; *Angew. Chem. Int. Ed.* **2008**, *47*, 2548.
[5] a) K. C. Nicolaou, A. Li, D. J. Edmonds, *Angew. Chem.* **2006**, *118*, 7244; *Angew. Chem. Int. Ed.* **2006**, *45*, 7086; b) K. C. Nicolaou, D. J. Edmonds, A. Li, G. S. Tria, *Angew. Chem.* **2007**, *119*, 4016; *Angew. Chem. Int. Ed.* **2007**, *46*, 3942; c) K. C. Nicolaou, Y. Tang, J. Wang, *Chem. Commun.* **2007**, 1922; d) K. C. Nicolaou, T. Lister, R. M. Denton, A. Montero, D. J. Edmonds, *Angew. Chem.* **2007**, *119*, 4796; *Angew. Chem. Int. Ed.* **2007**, *46*, 4712; e) K. C. Nicolaou, Y. Tang, J. Wang, A. F. Stepan, A. Li, A. Montero, *J. Am. Chem. Soc.* **2007**, *129*, 14850; f) Y. Zou, C.-H. Chen, C. D. Taylor, B. M. Foxman, B. B. Snider, *Org. Lett.* **2007**, *9*, 1825; g) P. Li, J. N. Payette, H. Yamamoto, *J. Am. Chem. Soc.* **2007**, *129*, 9534; h) G. Lalic, E. J. Corey, *Org. Lett.* **2007**, *9*, 4921; i) K. Tiefenbacher, J. Mulzer, *Angew. Chem.* **2007**, *119*, 8220; *Angew. Chem. Int. Ed.* **2007**, *46*, 8074; j) A. K. Ghosh, K. Xi, *Org. Lett.* **2007**, *9*, 4013; k) K. P. Kaliappan, V. Ravikumar, *Org. Lett.* **2007**, *9*, 2417; l) K. C. Nicolaou, D. Pappo, K. Y. Tsang, R. Gibe, D. Y.-K. Chen, *Angew. Chem.* **2008**, *120*, 958; *Angew. Chem. Int. Ed.* **2008**, *47*, 944; m) C. H. Kim, K. P. Jang, S. Y. Choi, Y. K. Chung, E. Lee, *Angew. Chem.* **2008**, *120*, 4073; *Angew. Chem. Int. Ed.* **2008**, *47*, 4009; n) K. B. Herath, C. Zhang, H. Jayasuriya, J. G. Ondeyka, D. L. Zink, B. Burgess, J. Wang, S. B. Singh, *Org. Lett.* **2008**, *10*, 1699; o) J. Hayashida, V. H. Rawal, *Angew. Chem.* **2008**, *120*, 4445; *Angew. Chem. Int. Ed.* **2008**, *47*, 4373.
[6] a) K. C. Nicolaou, G. S. Tria, D. J. Edmonds, *Angew. Chem.* **2008**, *120*, 1804; *Angew. Chem. Int. Ed.* **2008**, *47*, 1780; b) P. Heretsch, A. Giannis, *Synthesis* **2007**, 2614.
[7] a) M. Toyota, T. Wada, K. Fukumoto, M. Ihara, *J. Am. Chem. Soc.* **1998**, *120*, 4916; b) M. Toyota, M. Yokota, M. Ihara, *J. Am. Chem. Soc.* **2001**, *123*, 1856.
[8] Y. Chen, S.-K. Tian, L. Deng, *J. Am. Chem. Soc.* **2000**, *122*, 9542.
[9] H.-J. Gais, K. L. Lukas, W. A. Ball, S. Braun, H. J. Lindner, *Liebigs Ann. Chem.* **1986**, 687.
[10] Please see the Supporting Information for details.
[11] P. G. McDougal, J. G. Rico, Y.-I. Oh, B. D. Condon, *J. Org. Chem.* **1986**, *51*, 3388.
[12] Selected reviews, see: a) R. H. Grubbs, *Tetrahedron* **2004**, *60*, 7117; b) K. C. Nicolaou, P. G. Bulger, D. Sarlah, *Angew. Chem.* **2005**, *117*, 4564; *Angew. Chem. Int. Ed.* **2005**, *44*, 4490; c) A. Fürstner, *Angew. Chem.* **2000**, *112*, 3140; *Angew. Chem. Int. Ed.* **2000**, *39*, 3012.
[13] M. Scholl, S. Ding, C. W. Lee, R. H. Grubbs, *Org. Lett.* **1999**, *1*, 953.